These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 32493414)

  • 1. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
    Hua H; Kong Q; Yin J; Zhang J; Jiang Y
    J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights.
    Li H; Batth IS; Qu X; Xu L; Song N; Wang R; Liu Y
    Mol Cancer; 2017 Jan; 16(1):6. PubMed ID: 28137302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.
    Motallebnezhad M; Aghebati-Maleki L; Jadidi-Niaragh F; Nickho H; Samadi-Kafil H; Shamsasenjan K; Yousefi M
    Tumour Biol; 2016 Sep; 37(9):11711-11721. PubMed ID: 27444280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
    Jernberg-Wiklund H; Nilsson K
    Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF-1 receptor inhibitors in clinical trials--early lessons.
    Weroha SJ; Haluska P
    J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):471-83. PubMed ID: 19023648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting insulin-like growth factor in breast cancer therapeutics.
    Karamouzis MV; Papavassiliou AG
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.
    Simpson A; Petnga W; Macaulay VM; Weyer-Czernilofsky U; Bogenrieder T
    Target Oncol; 2017 Oct; 12(5):571-597. PubMed ID: 28815409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
    Singh P; Alex JM; Bast F
    Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance.
    Ngo MT; Jeng HY; Kuo YC; Diony Nanda J; Brahmadhi A; Ling TY; Chang TS; Huang YH
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
    Hendrickson AW; Haluska P
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the IGF system in cancer growth and metastasis: overview and recent insights.
    Samani AA; Yakar S; LeRoith D; Brodt P
    Endocr Rev; 2007 Feb; 28(1):20-47. PubMed ID: 16931767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
    Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.
    Karadeniz Z; Aynacıoğlu AŞ; Bilir A; Tuna MY
    Med Hypotheses; 2020 Jan; 134():109420. PubMed ID: 31634770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The insulin-like growth factor pathway as a target for cancer therapy.
    López-Calderero I; Sánchez Chávez E; García-Carbonero R
    Clin Transl Oncol; 2010 May; 12(5):326-38. PubMed ID: 20466617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance.
    Casa AJ; Dearth RK; Litzenburger BC; Lee AV; Cui X
    Front Biosci; 2008 May; 13():3273-87. PubMed ID: 18508432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between IGF-1R and other tumor promoting pathways.
    Liu C; Zhang Z; Tang H; Jiang Z; You L; Liao Y
    Curr Pharm Des; 2014; 20(17):2912-21. PubMed ID: 23944361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
    Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.
    Sachdev D; Yee D
    J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):27-39. PubMed ID: 16947084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.